These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670 [TBL] [Abstract][Full Text] [Related]
3. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. Murphy K; Gawchik S; Bernstein D; Andersen J; Pedersen MR J Negat Results Biomed; 2013 Jun; 12():10. PubMed ID: 23725348 [TBL] [Abstract][Full Text] [Related]
4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937 [TBL] [Abstract][Full Text] [Related]
5. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy. de Kam PJ; Zielen S; Bernstein JA; Berger U; Berger M; Cuevas M; Cypcar D; Fuhr-Horst A; Greisner WA; Jandl M; Laßmann S; Worm M; Matz J; Sher E; Smith C; Steven GC; Mösges R; Shamji MH; DuBuske L; Borghese F; Oluwayi K; Zwingers T; Seybold M; Armfield O; Heath MD; Hewings SJ; Kramer MF; Skinner MA Allergy; 2023 Oct; 78(10):2756-2766. PubMed ID: 37366581 [TBL] [Abstract][Full Text] [Related]
10. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. Durham SR; Emminger W; Kapp A; de Monchy JG; Rak S; Scadding GK; Wurtzen PA; Andersen JS; Tholstrup B; Riis B; Dahl R J Allergy Clin Immunol; 2012 Mar; 129(3):717-725.e5. PubMed ID: 22285278 [TBL] [Abstract][Full Text] [Related]
11. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets. Mösges R; Ritter B; Kayoko G; Allekotte S Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414 [TBL] [Abstract][Full Text] [Related]
12. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373 [TBL] [Abstract][Full Text] [Related]
13. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Hordijk GJ; Antvelink JB; Luwema RA Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731 [TBL] [Abstract][Full Text] [Related]
14. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Dahl R; Stender A; Rak S Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194 [TBL] [Abstract][Full Text] [Related]
15. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332 [TBL] [Abstract][Full Text] [Related]
17. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Horak F; Jaeger S; Worm M; Melac M; Didier A Clin Exp Allergy; 2009 Mar; 39(3):394-400. PubMed ID: 19134018 [TBL] [Abstract][Full Text] [Related]
18. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743 [TBL] [Abstract][Full Text] [Related]